Boston Scientific's ACURATE neo2™ Transcatheter Aortic Valve Receives NMPA Approval in China
Boston Scientific
Medical Device Manufacturer
Medical Device Media Reporting Pioneer
Share Professional Medical Device Knowledge
Boston Scientific ACURATE neo2™ Transcatheter Implantable Aortic Valve Approved by China's National Medical Products Administration
With the deepening of China's aging population, the incidence of valvular heart disease in China is gradually increasing. Aortic stenosis has become a common valvular heart disease among the elderly population, and transcatheter aortic valve replacement (TAVR) has become the first-line treatment for elderly patients with severe aortic stenosis.
Boston Scientific's ACURATE neo2™ Transcatheter Implantable Aortic Valve Approved by China's National Medical Products Administration, Offering More Diverse Treatment Options for Chinese TAVR Patients Meeting the Indications.
More exciting content
Welcome to follow WeChat Video Channel
Weigao Launches Major Strategic Layout
GE Healthcare Partners with Amazon, Enters Generative AI
29 Billion: This Largest Imaging Group to Be Sold
Mindray Medical: Already Covers Over 80% of IDN Medical Associations in the U.S.
120 Million, United Imaging Healthcare Takes Action
Hologic Completes One Imaging Acquisition
Optical Giant Enters the Endoscope Market
Samsung Enters the Market, China's AI Imaging Leader
$360 Billion: Largest Private Medical Device Company to Go Public
Centennial Medical Device Giant, Billion-Dollar Acquisition
Join【Device Family】WeChat Exchange GroupPlease add uniformlyAdministrator WeChat
Please uniformly note: Company + Name/Nickname (Otherwise, it will not be approved.)
BusinessBusiness cooperation email: qxzj@landianyiliao.com
